Novo Nordisk to boost US diabetes sales force by 60%

Share this article:
Danish drugmaker Novo Nordisk announced plans to boost the size of its US diabetes care sales force by 60%, or 700 reps, before mid-2007. Novo Nordisk controls approximately 40% of the US insulin market, which has grown increasingly competitive over the past two years following the launches of Lilly and Amylin’s GLP-1 inhibitor Byetta, Pfizer’s Exubera inhaled insulin and Merck’s DPP-4 inhibitor Januvia. Novo Nordisk said the goal of its field force expansion is to further support its currently marketed insulin analogs—Levemir, NovoLog Mix 70/30 and NovoLog—and gear up for the planned 2009 launch of its Liraglutide diabetes treatment. Analysts said the Novo sales force increase is a defensive move to help the company compete with Januvia, Exubera and Novartis’ yet-to-be approved Galvus. Poul la Cour, an analyst with Carnegie Bank, told United Press International that other companies won’t raise their sales force levels as a response. “That’s because their competitors…already have more sales reps than Novo. Eli Lilly might increase to support Byetta…But so far, that launch has been incredible, so they'll only increase if there's a slow-down.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...